Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1024 | 945 | 1024 | 1065 | 1191 | - |
Fund Return | 2.39% | -5.55% | 2.39% | 2.12% | 3.55% | - |
Place in category | 34 | 43 | 34 | 22 | 13 | - |
% in Category | 85 | 90 | 85 | 84 | 78 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CIFM China Emerging Power Class A | 5.06B | 11.72 | -13.07 | 12.10 | ||
CIFM China Emerging Power Class H | 5.06B | 11.70 | -13.10 | - | ||
CIFM Technology Qian Yan Alloc | 2.86B | 6.40 | -13.80 | - | ||
China Intl AsiaPacific Advantage St | 2.67B | 7.98 | -0.23 | 5.11 | ||
China International China Advanced | 2.47B | 9.94 | -12.24 | 6.51 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
GF Global Selction Eq QDII | 8.68B | 26.78 | 9.01 | 13.11 | ||
ChinaAMC Global Selective Fund QDII | 2.15B | 27.38 | -0.48 | 3.75 | ||
China Southern Intl Select Alloc | 1.52B | 1.67 | -5.74 | 1.81 | ||
ICBC Credit Suisse China Opportunit | 543.91M | 24.18 | 3.39 | 9.93 | ||
ICBC Credit Suisse Global Selected | 492.57M | 21.66 | 6.99 | 11.61 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk ADR | US6701002056 | 5.03 | 81.03 | +2.97% | |
Shell | GB00BP6MXD84 | 4.26 | 32.22 | +0.31% | |
SAP SE DRC | ARDEUT112034 | 2.76 | 53,200.00 | +0.57% | |
ASML Holding | NL0010273215 | 2.59 | 742.90 | +1.43% | |
TotalEnergies SE | FR0000120271 | 2.16 | 56.61 | -0.05% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Neutral | Neutral | Buy |
Technical Indicators | BUY | Strong Sell | BUY |
Summary | Neutral | Sell | Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review